In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Seattle Genetics Inc. netted $549mm through a public offering of 8.2mm common shares (including the overallotment) at $70. The company develops and sells cancer therapies, and will use the proceeds to support ongoing commercialization activities in the US and Canada for Adcetris (brentuximab vedotin, indicated for various lymphomas); for the potential upcoming launch of enfortumab vedotin (in Phase II for bladder cancer); and for additional R&D and corporate needs.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?